JP6905567B2 - 経皮吸収型パッチ - Google Patents
経皮吸収型パッチ Download PDFInfo
- Publication number
- JP6905567B2 JP6905567B2 JP2019206858A JP2019206858A JP6905567B2 JP 6905567 B2 JP6905567 B2 JP 6905567B2 JP 2019206858 A JP2019206858 A JP 2019206858A JP 2019206858 A JP2019206858 A JP 2019206858A JP 6905567 B2 JP6905567 B2 JP 6905567B2
- Authority
- JP
- Japan
- Prior art keywords
- sensitive adhesive
- drug
- pressure
- transdermal patch
- duro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 54
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 49
- 239000010410 layer Substances 0.000 claims description 49
- 229940079593 drug Drugs 0.000 claims description 45
- 239000003814 drug Substances 0.000 claims description 45
- 229960004136 rivastigmine Drugs 0.000 claims description 23
- 239000002562 thickening agent Substances 0.000 claims description 12
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 11
- 238000010521 absorption reaction Methods 0.000 claims description 9
- 239000000853 adhesive Substances 0.000 claims description 8
- 230000001070 adhesive effect Effects 0.000 claims description 8
- 230000035515 penetration Effects 0.000 claims description 8
- 229920005989 resin Polymers 0.000 claims description 7
- 239000011347 resin Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical group CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 6
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 5
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims description 4
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims description 4
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003961 penetration enhancing agent Substances 0.000 claims description 3
- NBPITTXSVKNVSL-UHFFFAOYSA-N C(C(O)CO)CCCCCCCCC=C/CCCCCCCC(=O)O.C(CCCCCCCC=C/CCCCCCCC)(=O)OCC(O)CO Chemical compound C(C(O)CO)CCCCCCCCC=C/CCCCCCCC(=O)O.C(CCCCCCCC=C/CCCCCCCC)(=O)OCC(O)CO NBPITTXSVKNVSL-UHFFFAOYSA-N 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 229940108366 exelon Drugs 0.000 description 25
- 238000012360 testing method Methods 0.000 description 25
- 238000004519 manufacturing process Methods 0.000 description 14
- -1 diethylene glycol monoethyl ester Chemical class 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 206010040880 Skin irritation Diseases 0.000 description 7
- 231100000475 skin irritation Toxicity 0.000 description 7
- 230000036556 skin irritation Effects 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 206010070835 Skin sensitisation Diseases 0.000 description 6
- 231100000370 skin sensitisation Toxicity 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- 231100000245 skin permeability Toxicity 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 239000012790 adhesive layer Substances 0.000 description 3
- 239000011247 coating layer Substances 0.000 description 3
- 230000003930 cognitive ability Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102100032404 Cholinesterase Human genes 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 108010053652 Butyrylcholinesterase Proteins 0.000 description 1
- YRRNLAFHTUJHOZ-QZOPMXJLSA-N CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO YRRNLAFHTUJHOZ-QZOPMXJLSA-N 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- ILMMCBFQWHPTHE-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O.CCCC(O)O ILMMCBFQWHPTHE-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 238000009506 drug dissolution testing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
0=≧90%の粘着(基本的に皮膚から剥離していない)
1=≧75%〜<90%の粘着(パッチの一部辺縁のみ皮膚上から剥離している)
2=≧50%〜<75%の粘着(半分未満のパッチが皮膚上から剥離している)
3=>0%〜<50%の粘着、但し脱落なし(半分を超えるパッチが皮膚上から剥離しているが脱落していない)
4=0%の粘着- パッチが脱落している(パッチが完全に皮膚から剥離している)
Claims (9)
- 経皮吸収型パッチであって、
バッキング層と、
リバスチグミン(rivastigmine)またはその薬学的に許容可能な塩と、
粘着剤と、
ジエチレングリコールモノエチルエーテル(diethylene glycol monoethyl ether)と、モノオレイン酸グリセリル(glyceryl monooleate)である2種類の皮膚浸透促進剤を含む薬物含有粘着剤層と、
剥離ライナーと、
を含み、そのうち、該薬物含有粘着剤層が該バッキング層と該剥離ライナーの間に配置され、該薬物含有粘着剤層の総重量を基準として、該リバスチグミンまたはその薬学的に許容可能な塩の含有量が10wt%〜30wt%の間であり、該粘着剤が感圧接着剤を含むことを特徴とする、経皮吸収型パッチ。 - 前記薬物含有粘着剤層の総重量を基準として、該粘着剤の含有量が50wt%〜80wt%の間であることを特徴とする、請求項1に記載の経皮吸収型パッチ。
- 前記感圧接着剤がアクリル系感圧接着剤であることを特徴とする、請求項1に記載の経皮吸収型パッチ。
- 前記該薬物含有粘着剤層の総重量を基準として、該2種類の皮膚浸透促進剤の含有量が0.1wt%〜10wt%の間である、ことを特徴とする、請求項1に記載の経皮吸収型パッチ。
- 前記薬物含有粘着剤層がさらに増粘剤を含むことを特徴とする、請求項1に記載の経皮吸収型パッチ。
- 前記薬物含有粘着剤層の総重量を基準として、該増粘剤の含有量が0.1wt%〜15wt%の間であることを特徴とする、請求項5に記載の経皮吸収型パッチ。
- 前記増粘剤が樹脂であることを特徴とする、請求項5に記載の経皮吸収型パッチ。
- 経皮吸収型パッチであって、
バッキング層と、
10wt%〜30wt%のリバスチグミン(rivastigmine)またはその薬学的に許容可能な塩と、
50wt%〜80wt%のアクリル系感圧接着剤と、
0.1wt%〜10wt%の2種類の皮膚浸透促進剤と、
0.1wt%〜15wt%の増粘剤を含み、前記2種類の皮膚浸透促進剤がジエチレングリコールモノエチルエーテル(diethylene glycol monoethyl ether)と、モノオレイン酸グリセリル(glyceryl monooleate)である薬物含有粘着剤層と、
剥離ライナーと、
を含み、そのうち、該薬物含有粘着剤層が該バッキング層と、該剥離ライナーとの間に配置されることを特徴とする、経皮吸収型パッチ。 - 前記増粘剤が樹脂であることを特徴とする、請求項8に記載の経皮吸収型パッチ。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW107140732 | 2018-11-16 | ||
TW107140732A TWI720366B (zh) | 2018-11-16 | 2018-11-16 | 經皮吸收貼片 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020083885A JP2020083885A (ja) | 2020-06-04 |
JP6905567B2 true JP6905567B2 (ja) | 2021-07-21 |
Family
ID=70728858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019206858A Active JP6905567B2 (ja) | 2018-11-16 | 2019-11-15 | 経皮吸収型パッチ |
Country Status (3)
Country | Link |
---|---|
US (1) | US11000483B2 (ja) |
JP (1) | JP6905567B2 (ja) |
TW (1) | TWI720366B (ja) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100087768A1 (en) * | 2008-10-02 | 2010-04-08 | Forlano Paula | Transdermal drug delivery system for liquid active ingredient |
DE102010024105A1 (de) * | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
SG11201404815YA (en) | 2012-02-28 | 2014-10-30 | Nichiban Kk | Transdermal patch |
US20140271866A1 (en) | 2013-03-15 | 2014-09-18 | Nal Pharmaceuticals, Ltd. | Transdermal drug delivery system containing rivastigmine |
WO2015133329A1 (ja) * | 2014-03-06 | 2015-09-11 | 帝國製薬株式会社 | 貼付製剤 |
CN106413695B (zh) * | 2014-04-08 | 2019-12-10 | 帝国制药美国公司 | 利伐斯的明透皮组合物及其使用方法 |
JP2016069287A (ja) * | 2014-09-26 | 2016-05-09 | 祐徳薬品工業株式会社 | リバスチグミン含有経皮吸収型貼付製剤 |
US10149828B2 (en) * | 2015-01-09 | 2018-12-11 | Chase Pharmaceuticals Corporation | Oxybutynin transdermal therapeutic system combination |
EP3251663A1 (en) * | 2015-01-30 | 2017-12-06 | Toyo Ink Sc Holdings Co., Ltd. | Adhesive patch |
CN107427472B (zh) * | 2015-03-02 | 2021-04-30 | 久光制药株式会社 | 贴附剂 |
-
2018
- 2018-11-16 TW TW107140732A patent/TWI720366B/zh active
-
2019
- 2019-10-02 US US16/590,620 patent/US11000483B2/en active Active
- 2019-11-15 JP JP2019206858A patent/JP6905567B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US20200155476A1 (en) | 2020-05-21 |
US11000483B2 (en) | 2021-05-11 |
JP2020083885A (ja) | 2020-06-04 |
TWI720366B (zh) | 2021-03-01 |
TW202019396A (zh) | 2020-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101796771B1 (ko) | 도네페질을 유효성분으로 함유하는 경피흡수제제 | |
KR20150036479A (ko) | 첩부제 | |
US20180256562A1 (en) | Transdermal Delivery System | |
EP0315219B1 (en) | Pharmaceutical compositions | |
KR20130121139A (ko) | 도네페질 경피 패치제 | |
US20160271075A1 (en) | Fentanyl-containing adhesive preparation for external use | |
JP2003528037A (ja) | 気管支拡張剤ツロブテロールを皮膚から投与するための塩酸ツロブテロールを含む経皮治療システム | |
KR100929560B1 (ko) | 그라니세트론을 함유한 매트릭스 형태의 경피 흡수제 | |
JP2002537244A (ja) | デオキシペガニン経皮治療系 | |
JP6905567B2 (ja) | 経皮吸収型パッチ | |
CN116036055A (zh) | 一种含甲磺酸雷沙吉兰的透皮贴剂及其制备方法 | |
US8968774B2 (en) | Preparation and composition of meloxicam transdermal drug delivery system | |
AU2009210075B2 (en) | Fentanyl-containing patch for external use | |
CN111195242B (zh) | 经皮吸收贴片 | |
JP3980634B2 (ja) | 活性物質モルフィン−6−グルクロニドを含む全身的経皮投与用医薬組成物 | |
JP6864968B2 (ja) | 貼付剤 | |
KR100439658B1 (ko) | 이소소르비드 디니트레이트를 활성성분으로 하는경피흡수제제 및 그 제조방법 | |
EP3810101A1 (en) | Transdermal therapeutic system containing rivastigmine | |
IE69475B1 (en) | Pharmaceutical compositions | |
WO2014159778A1 (en) | Transdermal drug delivery system containing fentanyl |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191115 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201013 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210104 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210608 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210625 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6905567 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |